GPE – Page 3 – Talk Bio

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

About 5% of CBER and CDER Left After FDA Staff Cuts, Analysis Finds

2 months ago talkbio0Tagged Biological Factors, CBER, CDER, Drug Approval Process, drug review, layoffs, Staff, Trump administration, United States Food and Drug Administration

FDA layoffs; CBER; CDER; drug review; biologics; staff cuts; Trump administration; drug approval process

Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey

2 months ago talkbio0Tagged Corporate, flagship office, Health care facility, innovation, Market, Morristown, sanofi, U.S.

Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

2 months ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures

2 months ago talkbio0Tagged customs loophole, drug import duties, Drug Industry, first, minimis exemption, sale rule, tariff avoidance, trade compliance, Trump administration, U.S., US tariffs

first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption

Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial

2 months ago talkbio0Tagged AAVS1 gene, ASGCT, Clinical Trials, Dosage, gene therapy, Individual Adjustment, Lymphohistiocytosis, Hemophagocytic, Measures, MECP2 gene, Neurogene, NGN-401, Rett Syndrome, Safety, United States Food and Drug Administration

Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment

Sanofi Announces $20 Billion US Investment Over Five Years

2 months ago talkbio0Tagged Big Pharma, development aspects, domestic partnerships, Drug Industry, Investments, Manufacturing, research, sanofi, Surgical construction, tariffs, U.S.

Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships